Literature DB >> 19731081

Molecular study of CEBPA in familial hematological malignancies.

R El Abed1, V Bourdon, L Huiart, F Eisinger, A Khelif, M Frenay, P Gesta, L Demange, H Dreyfus, V Bonadona, C Dugast, H Zattara, L Faivre, T Noguchi, R Sauvan, Z Soua, H Sobol.   

Abstract

Familial aggregation in patients with several haematological malignancies has been described, but the genetic basis for this familial clustering is not known. Few genes predisposing to familial haematological malignancies have been identified, among which RUNX1 and CEBPA have been described as predisposing genes to acute myeloid leukemia (AML). Recent studies on RUNX1 suggest that germline mutations in this gene predispose to a larger panel of familial haematological malignancies than AML. In order to strengthen this hypothesis, we have screened CEBPA for germline mutations in several families presenting aggregation of hematological malignancies (including chronic or acute, lymphoid or myeloid leukemias, Hodgkin's or non Hodgkin's lymphomas, and myeloproliferative or myelodysplastic syndromes) with or without solid tumours. Although no deleterious mutations were found, we report two novel and rare variants of uncertain significance. In addition, we confirm that the in frame insertion c.1175_1180dup (p.P194_H195dup) is a germline polymorphism.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19731081     DOI: 10.1007/s10689-009-9289-x

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  14 in total

1.  Further evidence that germline CEBPA mutations cause dominant inheritance of acute myeloid leukaemia.

Authors:  G S Sellick; H E Spendlove; D Catovsky; K Pritchard-Jones; R S Houlston
Journal:  Leukemia       Date:  2005-07       Impact factor: 11.528

2.  A recurrent in-frame insertion in a CEBPA transactivation domain is a polymorphism rather than a mutation that does not affect gene expression profiling-based clustering of AML.

Authors:  Bas J Wouters; Irene Louwers; Peter J M Valk; Bob Löwenberg; Ruud Delwel
Journal:  Blood       Date:  2007-01-01       Impact factor: 22.113

3.  Genetic changes of CEBPA in cancer: mutations or polymorphisms?

Authors:  Carlos Resende; Gonçalo Regalo; Cecília Durães; Fátima Carneiro; José C Machado
Journal:  J Clin Oncol       Date:  2007-06-10       Impact factor: 44.544

4.  Another pedigree with familial acute myeloid leukemia and germline CEBPA mutation.

Authors:  A Renneville; V Mialou; N Philippe; S Kagialis-Girard; V Biggio; M-T Zabot; X Thomas; Y Bertrand; C Preudhomme
Journal:  Leukemia       Date:  2008-10-23       Impact factor: 11.528

5.  Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome.

Authors:  Bas J Wouters; Bob Löwenberg; Claudia A J Erpelinck-Verschueren; Wim L J van Putten; Peter J M Valk; Ruud Delwel
Journal:  Blood       Date:  2009-01-26       Impact factor: 22.113

6.  Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells.

Authors:  Liang-In Lin; Chien-Yuan Chen; Dong-Tsamn Lin; Woei Tsay; Jih-Luh Tang; You-Chia Yeh; Hwei-Ling Shen; Fang-Hsien Su; Ming Yao; Sheng-Yi Huang; Hwei-Fang Tien
Journal:  Clin Cancer Res       Date:  2005-02-15       Impact factor: 12.531

7.  Mutation of CEBPA in familial acute myeloid leukemia.

Authors:  Matthew L Smith; Jamie D Cavenagh; T Andrew Lister; Jude Fitzgibbon
Journal:  N Engl J Med       Date:  2004-12-02       Impact factor: 91.245

8.  Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia.

Authors:  Thomas Pabst; Marianne Eyholzer; Simon Haefliger; Julian Schardt; Beatrice U Mueller
Journal:  J Clin Oncol       Date:  2008-09-02       Impact factor: 44.544

9.  CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma.

Authors:  Ota Fuchs; Dana Provaznikova; Marcela Kocova; Arnost Kostecka; Pavla Cvekova; Radana Neuwirtova; Petr Kobylka; Jaroslav Cermak; Jana Brezinova; Jiri Schwarz; Jana Markova; Peter Salaj; Hana Klamova; Jacqueline Maaloufova; Petr Lemez; Ludmila Novakova; Katerina Benesova
Journal:  Blood Cells Mol Dis       Date:  2008-01-08       Impact factor: 3.039

Review 10.  Growth-inhibiting activity of transcription factor C/EBPalpha, its role in haematopoiesis and its tumour suppressor or oncogenic properties in leukaemias.

Authors:  O Fuchs
Journal:  Folia Biol (Praha)       Date:  2007       Impact factor: 0.906

View more
  2 in total

1.  Familial hematological malignancies: ASXL1 gene investigation.

Authors:  W S Hamadou; R E Abed; S Besbes; V Bourdon; A Fabre; Y B Youssef; M A Laatiri; F Eisinger; V Mari; P Gesta; H Dreyfus; V Bonadona; C Dugast; H Zattara; L Faivre; S Y Jemni; T Noguchi; A Khélif; H Sobol; Z Soua
Journal:  Clin Transl Oncol       Date:  2015-08-19       Impact factor: 3.405

2.  Association between the CEBPA and c-MYC genes expression levels and acute myeloid leukemia pathogenesis and development.

Authors:  Adrian Krygier; Dagmara Szmajda-Krygier; Aleksandra Sałagacka-Kubiak; Krzysztof Jamroziak; Marta Żebrowska-Nawrocka; Ewa Balcerczak
Journal:  Med Oncol       Date:  2020-11-10       Impact factor: 3.064

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.